Indmedica Home | About Indmedica | Medical Jobs | Advertise On Indmedica
Search Indmedica Web
Indmedica - India's premier medical portal

Biomedical Research

Association between glycaemic control and serum lipid profile in type 2 diabetic patients: Glycated haemoglobin as a dual biomarker

Author(s): Ram Vinod Mahato, Prajwal Gyawali, Pramod Psd. Raut, Prashant Regmi, Khelanand Psd. Singh, Dipendra Raj Pandeya, Prabin Gyawali

Vol. 22, No. 3 (2011-07 - 2011-09)

Ram Vinod Mahato1, Prajwal Gyawali2, Pramod Psd. Raut3, Prashant Regmi2, Khelanand Psd. Singh2, Dipendra Raj Pandeya4, Prabin Gyawali5

(1) Department of Biochemistry, Peoples Dental College and Hospital, Kathmandu, Nepal
(2) Department of Biochemistry, Institute of Medicine, Kathmandu, Nepal
(3) Department of Diagnostic Laboratory, Civil Service Hospital, Kathmandu, Nepal
(4) Laboratory of Genetics, Department of Microbiology and Immunology, Institute for Medical Science, Chonbuk Na-tional University Medical School, Chonju, Chonbuk 561-756, South Korea
(5) Department of Clinical Biochemistry, Dhulikhel Hospital-Kathmandu University Hospital, Dhulikhel, Kavre, Nepal

Abstract

Patients with type 2 diabetes have an increased prevalence of lipid abnormalities, contribut-ing to their high risk of cardiovascular diseases (CVD). This study is an attempt to evaluate the diagnostic value of Glycated haemoglobin (HbA1c) in predicting diabetic dyslipidemia. Venous blood samples were collected from 294 type 2 diabetic patients. The whole blood and sera were analyzed for HbA1c, fasting blood glucose (FBG) and lipid profile panel test. Dyslipidemia was defined as per the National Cholesterol Education Programme (NCEP) Adult Treatment Panel (ATP) III guidelines. Diabetes was defined as per American diabetes association criteria. The statistical analysis was done by SPSS statistical package version 13.0.In our present study 92 (80.70%) females out of 114 and 150 (83.33 ) males out of 180 were found to be dyslipidemic. HbA1c demonstrated positive and significant correlations with total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipopro-tein cholesterol (HDL-C) and LDL-C ratio, non-HDL-C and TC/HDL-C ratio. Patients with HbA1c value > 7.0 had significantly higher value of TC, Triacylglycerol (TAG), LDL-C, LDL-C/HDL-C ratio, non-HDL-C and TC/HDL-C ratio as compared to the patients with HbA1c ≤ 7.0%. However, there was no significant difference in value of HDL-C between two groups. HbA1c can be used as a potential biomarker for predicting dyslipidemia in type 2 diabetic patients in addition to glycemic control.

Keywords: Diabetes mellitus, Dyslipidemia, Glycated hemoglobin, Lipid Profile panel, Biomarker
Accepted March 2011

Introduction

Diabetes mellitus is a group of metabolic disease charac-terized by hyperglycaemia resulting from defects in insu-lin secretion, insulin action, or both. Diabetes causes about 5% of all deaths globally each year. The chronic hyperglycaemia of diabetes is associated with long-term damage, dysfunction, and failure of various organs, espe-cially the eyes, kidneys, nerves, heart, and blood ves-sels.50% of people with diabetes die of cardiovascular disease (primarily heart disease and stroke). [1, 2].

Diabetic patients with accompanied (but often unnoticed) dyslipidemia are soft targets of cardiovascular deaths. Patients with type 2 diabetes often exhibit an atherogenic lipid profile, which greatly increases their risk of CVD compared with people without diabetes. An early inter-vention to normalize circulating lipids has been shown to reduce cardiovascular complications and mortality. [3,4].

Glycated hemoglobin (HbA1c) is a routinely used marker for long-term glycemic control. In accordance with its function as an indicator for the mean blood glucose level, HbA1c predicts the risk for the development of diabetic complications in diabetes patients[2].Apart from classical risk factors like dyslipidemia, elevated HbA1c has now been regarded as an independent risk factor for CVD in subjects with or without diabetes. Estimated risk of CVD has shown to be increased by 18% for each 1% increase in absolute HbA1c value in diabetic population [6]. Posi-tive relationship between HbA1c and CVD has been demonstrated in non-diabetic cases even within normal range of HbA1c [7 8 9 10]. The aim of this study was to find out association between glycaemic control (HbA1ch3. as a marker) and serum lipid profile in Nepalese type 2 diabetic patients.

Materials and methods

A total of 294 type 2 diabetic patients (180 males and 114 females) visiting the OPD of Civil Service Hospital, Kathmandu,Nepal from October 2009 to May 2010 were included in this study. Venous blood samples were col-lected from all the subjects after at least 8 hours fasting. The Serum was later used for analyzingFasting Blood Glucosse ( FBG), Lipid Profile Panel Test-Serum Total cholesterol(TC),HDL-cholesterol(HDL-C), Triacylglyc-erol (TAG),Risk ratio (TC/HDL-C) by using Mindray BA-AT 80 (Human Diagnostics Reagents, Germany) and Indirect LDL-cholesterol and Non-HDL Cholesterol(Non HDL-C) was calculated by Friedwald and Frederickson formula.HbA1c was estimated by using Ion exchange chromatography (Crest A Coral clinical system,USA).

For serum lipid reference level, National Cholesterol Education Programme (NCEP) Adult Treatment Panel III (ATP III) guideline was referred. According to NCEP-ATPIII guideline, hypercholesterolemia is defined as TC>200 mg/dl, high LDL-C when value >100 mg/dl, hy-pertriglyceridemia as TAG >150 mg/dl and low HDL-C when value <40 mg/dl. Dyslipidemia was defined by presence of one or more than one abnormal serum lipid concentration. Diabetes was defined as per American Diabetes Association (ADA) criteria. The data were evaluated by SPSS statistical package version 13.0. Pear-son’s correlation test was performed to examine various correlations. Independent samples t-test (2-tailed) was used to compare means of different parameters. Value of HbA1c was given as percentage of total haemoglobin and values of all other parameters were given in mg/dl. All Values are expressed as mean ± standard error of mean. The results were considered non-significant when P > 0.05.

Results

Among total 294 type 2 diabetic individuals included in this study, 180 were male and 114 were female. The mean age ± SEM of male and female subjects were 62.72±10.24 and 55.86 ± 12.08 years respectively. The mean value of HbA1c and FBG were slightly higher in females in comparison to male patients but the differences were not significant. Among the circulating lipids, TC and LDL-C were significantly higher (P<0.05) in females patients. Although the mean level of TAG was slightly lower and of HDL-C slightly higher in females than males, these differences were statistically non-significant (Table 1).

Hypercholesterolemia was found in 82(27.89%) individu-als. Similarly, hypertriglyceridemia was found in 186(63.26%) individuals, decreased HDL-C was found in 46(15.6%) individuals and increased LDL-C was found in 140(47.6%) individuals. Among the diabetic individuals, 106(36.05%) individuals had only one abnormal lipid profile parameter, 88(29.93) had two abnormal lipid pa-rameter and 68(23.12%) individuals had more than 2 ab-normal lipid profile parameter. According to NCEP-ATPIII guideline, 92(80.70%) females out of 114 and 150 (83.33 %) males out of 180 were dyslipidemic.

Highly significant correlation was observed between FBG and HbA1c (P=0.000). HbA1c also demonstrated direct and significant correlations with TC (P=0.017), LDL-C (P=0.015), LDL-C/HDL-C ratio (P=0.011), Non-HDL-C (P=0.011) and Risk ratio (P=0.005). The correlation of HbA1c with TAG was positive (P=0.169) and with that of HDL-C was negative (P=0.596) but it was statistically non-significant (Figure 1). Also, HbA1c was found to be a predictor of hypercholesterolemia (p=0.017; R2=0.039) and high LDL-C (p=0.015, R2 =0.040) by linear regres-sion analysis. However, HDL-C (p=0.596, R2 = 0.002) and TAG (p=0.169, R2=0.013) did not show significant association with HbA1c in regression analysis.

Table 1. Lipid Profile parameters result of Male and Female Type 2 Diabetic Patients

Parameter Males (n=180) Females (n=114) P-value
Mean ± SEM Mean ± SEM
FBG 149.44±5.83 159.4±7.56 0.296
TC 177.03±3.99 196.68±7.23 0.011٭
TAG 191.21±8.37 183.61±9.43 0.558
HDL-C 45.93±0.61 46.52±0.97 0.593
LDL-C 92.86±3.85 113.89±5.47 0.002٭
HbA1c 7.20±0.10 7.53±0.17 0.105

٭statistically significant

Fig 1

Figure 1. Correlations between HbA1c and FBG & Lipid profile Panel Parameters.

Table 2. Biochemical Parameters categorized by patients’ glycemic control (HbA1c)

Parameter
Glycated Hemoglobin (HbA1c)
≤7.0 (n=82) >7.0 (n=85) P-value
Mean ± SEM Mean ± SEM
TC 174.89±5.29 181.78±5.19 0.024٭
TAG 173.05±7.88 199.36±9.07 0.03٭
HDL-C 46.79±0.84 45.71±0.68 0.322
LDL-C 91.63±4.27 107.86±4.60 0.011٭
Non-HDL-C 127.03±4.72 149.20±5.32 0.002٭
Risk ratio (TC/HDL-C) 3.76±0.098 4.31±0.127 0.001٭
LDL-C/HDL-C 1.98±0.089 2.43±0.107 0.002٭
FBG 123.56±3.03 175.0±6.79 0.000٭

٭statistically significant

Diabetic patients were classified into 2 groups as per their glycemic index; first group consists of patients with HbA1c value ≤7.0 % and second group consists of pa-tients with HbA1c value >7.0%. Patients with HbA1c value >7.0% had significantly higher value of TC (P=0.024), TG (P=0.030), LDL-C (P=0.011), Non-HDL-C, LDL-C/HDL-C ratio and Risk ratio as compared to the patients with HbA1c value ≤ 7.0% (Table 2).

Discussion

In the present study, we have evaluated the pattern of lipid profile parameters in diabetic subjects and its corre-lation with HbA1c. The levels of HbA1c and FBG did not differ significantly between male and female. Although there were no significant difference in TAG and HDL-C levels between male and female, the levels of TC and LDL-C were significantly higher in female as compared to male type 2 diabetic patients. This finding is in agree-ment with the previous studies [11 12 13 14 15 16]. Hy-perlipidemia in females may be attributed to the effects of sex hormones on body fat distribution, which leads to differences in altered lipoproteins [17].

This study reveals high prevalence of hypercholes-terolemia, hypertriglyceridemia, high LDL-C and low HDL-C levels which are well known risk factors for car-diovascular diseases. Insulin affects the liver apolipopro-tein production. It regulates the enzymatic activity of lipoprotein lipase (LpL) and Cholesterol ester transport protein. All these factors are likely cause of dyslipidemia in Diabetes mellitus [18]. Moreover, insulin deficiency reduces the activity of hepatic lipase and several steps in the production of biologically active LpL may be altered in DM [19]. The main disorder in lipid metabolism was hypertriglyceridemia in our study. This finding is in con-cord with our previous study [20]. In the study of Sehran et al in Pakistan, 54% diabetic individuals had elevated LDL-C and > 50% individuals had increased TG. These findings are similar to our study. But in contrast to our present study, they reported low HDL-C in 73% individu-als.

A highly significant correlation between HbA1c and FBG in our study is similar with various previous studies[21-23]. We also observed significant correlations between HbA1c and TC, LDL-C and LDL-C/HDL-C ratio. In various studies, HbA1c level was eminent as showing positive correlation with TC, LDL-C and TAG in diabetic patients[24-26]. Our study also showed a significant cor-relation between HbA1c and non-HDL-C (P=0.009). Non-HDL-C was shown to be the stronger predictor of CVD in diabetic population by ‘The Strong Heart Study’ (data evaluated by Lu et al), with hazard ratios of 2.23 and 1.80 respectively in male and female[27]. This study showed that increasing Non-HDL cholesterol concentra-tions had significant, curvilinear relationships with CVD and CHD risk (P <0.001). Moreover, NCEP ATPIII has recommended using Non-HDL cholesterol in assessing CVD risk in patients with diabetes. The correlation of HbA1c with non-HDL-C was found to be more signifi-cant than correlation of HbA1c with other lipid parame-ters except for LDL-C/ HDL-C and Risk ratio in our study. The measurement of Non-HDL-C is simple which can be conducted even in non-fasting state of patients and can be determined regardless of TAG concentration. Hence, Non-HDL cholesterol can be of great value in de-termining dyslipidemia in diabetic subjects. Risk ratio showed the strongest correlation with HbA1c in our study. In the prospective cohort study with inclusion of 418 Type 2 diabetic individuals with follow-up until the

Association between glycaemic control and serum lipid profile in type 2 diabetic patients appearance of a cardiovascular event, Gimeno-Orna JA et al[28], showed that the main lipid predictor of vascular events was mean TC/HDL-C ratio with hazard ratio (HR) of 1.46. In the same study, the predictive power of the TC/HDL ratio was found to be higher than that of Non-HDL cholesterol and study concluded that TC/HDL-C can be used as a treatment guides for diabetic dyslipide-mia. Total number of apo-B containing particles and small LDL-C Particles are increased in diabetes and these metabolic abnormalities are better reflected by TC/HDL-C ratio and Non-HDL-C than LDL-C alone [ 29 30]. Significant association of HbA1c with various lipid pa-rameters, Non-HDL-C, LDL-C/ HDL-C ratio and TC/HDL-C ratio in present study suggests the importance of glycemic control in order to control dyslipidemia.

The Diabetes complications and control trial (DCCT) es-tablished HbA1c as the gold standard of glycemic control. The level of HbA1c value ≤7.0% was said to be appropri-ate for reducing the risk of cardiovascular complica-tions[31]. In the present study, we divided diabetic pa-tients into 2 groups as per the HbA1c cutoff of 7.0%. The diabetic patients with HbA1c value > 7.0% exhibited a significant increase in TC, LDL-C, TAG, LDL-C/HDL-C ratio, Non-HDL-C and Risk ratio without any significant alteration in HDL-C in comparison to patients with HbA1c value ≤7.0%. Khan HA et al [32] showed the impact of glycaemic control on various lipid parameters in which the diabetic patients were categorized into 3 groups according to their HbA1c levels: group 1, good glycaemic control (HbA1c<6%); group 2, poor glycaemic control (HbA1c >6%–9%) and group 3, worst glycaemic control (HbA1c>9%). Though there was no significant differences in LDL–C in 3 groups with regard to glycae-mic control, alterations in other lipid parameters were statistically significant in three different groups. Severity of dyslipidemia increases in patients with higher HbA1c value. As elevated HbA1c and dyslipidemia are inde-pendent risk factors of CVD, diabetic patients with ele-vated HbA1c and dyslipidemia can be considered as a very high risk group for CVD. Improving glycaemic con-trol can substantially reduce the risk of cardiovascular events in diabetics [33]. It has been estimated that reduc-ing the HbA1c level by 0.2% could lower the mortality by 10% [34].

Conclusion

Significant correlation between HbA1c and various circu-lating lipid parameters and significant difference of lipid parameters in two groups (≤7.0% and >7.0%) of glycated hemoglobin indicates that HbA1c can be used as a poten-tial biomarker for predicting dyslipidemia in type 2 dia-betic patients in addition to glycemic control hence early diagnosis can be accomplished through relatively inex-pensive blood testing.

Acknowledgement

The authors are grateful to Mr. Anil Singh Basnyat and all the staff at the Clinical Bio-chemistry Laboratory, Civil Service Hospital, Kathmandu Nepal for their co-operation and skillful technical assistance.

References

  1. Diabtes.http://.who.int/mediacentre/factsheets/fs312/en/ index.html (Updated on November 2009).
  2. Glycosylaed Haemoglobin, HbA1C.hptt:// clinlabnavi-gator.com/test-interpretations/haemoglobin-a1c.html? letter=h (Updated on 18 June 2010).
  3. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
  4. Windler E. What is the consequence of an abnormal lipid profile in patients with type 2 diabetes or the metabolic syndrome? Atheroscler Suppl 2005;6: 11-14.
  5. Marshall SM and Barth JH. Standardization of HbA1c measurements – a consensus statement. Diabetic Medi-cine 2000; 17:5-176.
  6. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: glycosy-lated hemoglobin and cardiovascular disease in diabe-tes mellitus. Ann Intern Med 2004; 14: 421-431.
  7. Khaw KT, Wareham N, Bingham S, Luben R, Welch A and Day N. Association of hemoglobin A1c with car-diovascular disease and mortality in adults: the Euro-pean Prospective Investigation into Cancer in Norfolk. Ann Intern Med 2004; 141: 413-420.
  8. Hill JB, Kessler G. An automated determination of glucose utilizing a glucose oxidase-peroxidase system. J Lab Clin Med 1961; 57: 970-980.
  9. Deeg R, Ziegenhorn J. Kinetic enzymatic method for automated determination of total cholesterol in serum. Clin Chem 1983; 29: 1798-802.
  10. Bucolo G, David H. Quantitative determination of se-rum triglycerides by the use of enzymes. Clin Chem 1973; 19: 476-482.
  11. Assmann G, Schriewer H, Schmitz G, Hägele EO. Quantification of high-density-lipoprotein cholesterol by precipitation with phosphotungstic acid/MgCl2. Clin Chem 1983; 29: 2026-2030.
  12. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein choles-terol in plasma without use of the preparative ultracen-trifuge. Clin Chem 1972; 18: 499-502.
  13. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) [spe-cial communication]. JAMA 2001; 285:2486- 2497.
  14. American Diabetes Association. Diagnosis and classifi-cation of Diabetes Mellitus. Diabetes Care 2010; 33:s6 2-s69.
  15. Wexler DJ, Grant RW, Meigs JB, Nathan DM, Cagliero E. Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care 2005; 28: 514-520.
  16. Diabetes Prevention Program Research Group. Lipid, lipoproteins, C-reactive protein, and hemostatic factors at baseline in the diabetes prevention program. Diabe-tes Care 2005; 28: 2472-2479.
  17. Sibley SD, Thomas W, de Boer I, Brunzell JD, Steffes MW. Gender and elevated albumin excretion in the Diabetes Control and Complications trial/ Epidemiol-ogy of Diabetes Interventions and Complications (DCCT/EDIC) cohort: role of central obesity. Am J Kidney Dis 2006; 47: 223-232.
  18. Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res 1996; 37: 693-707.
  19. Tavangar K, Murata Y, Pedersen ME, Goers JF, Hoff-man AR, Kraemer FB. Regulation of lipoprotein lipase in the diabetic rat. J Clin Invest 1992; 90: 1672-1678.
  20. Regmi P, Gyawali P, Shrestha R, Sigdel M, Mehta KD, Majhi S. Pattern of Dyslipidemia in Type 2 Dia-betic Subjects in Eastern Nepal. JNAMLS 2009; 10: 11-13.
  21. Ito C, Maeda R, Ishida S, Sasaki H, Harada H. Correla-tion among fasting plasma glucose, two-hour plasma glucose levels in OGTT and HbA1c. Diabetes Res Clin Pract 2000; 50: 225-230.
  22. Ko GT, Chan JC, Woo J, Lau E, Yeung VT, Chow CC, et al. Glycated hemoglobin and cardiovascular risk fac-tors in Chinese subjects with normal glucose tolerance. Diabet Med 1998;15: 573-578.
  23. Rosediani M, Azidah AK, Mafauzy M. Correlation between fasting plasma glucose, post prandial glucose and glycated haemoglobin and fructosamine. Med J Malaysia 2006; 61: 67-71.
  24. Erciyas F, Taneli F, Arslan B, Uslu Y. Glycemic con-trol, oxidative stress and lipid profile in children with type 1 Diabetes Mellitus. Arch Med Res 2004; 35:134-140.
  25. Andersen GE, Christiansen JS, Mortensen HB, Christiansen KM, Predersen-Bjerguard L, Kastrup KW, et al. Plasma lipid and lipoprotein in type 1 diabetic children and adolescent in relation to metabolic regula-tion,obesity and genetic hyperlipoprotenimia. Actu paediator Scand 1983; 72: 361-365.
  26. Ohta T, Nishiyama S, Nakamura T, Saku K, Maung KK, Matsuda I. Predominance of large low density lipoprotein particles and lower fractional esterification rate of cholesterol in high density lipoprotein in chil-dren with insulin-dependent diabetes mellitus. Eur J Pediatr 1998; 157: 276-281.
  27. Lu W, Resnick HE, Jablonski KA, Jones KL, Jain AK, Howard WJ, et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care 2003; 26: 16-23.
  28. Gimeno-Orna JA, Faure-Nogueras E and Sancho-Serrano MA. Usefulness of total cholesterol/HDL-cholesterol ratio in the management of diabetic dyslipi-daemia. Diabet Med 2005; 22: 26-31.
  29. Lemieux I, Lamarche B, Couillard C, Pascot A, Cantin B, Bergeron J, et al. Total cholesterol /HDL cholesterol ratio vs LDL cholesterol /HDL cholesterol ratio as in-dices of ischemic heart disease risk in men. The Que-bec Cardiovascular Study. Arch Intern Med 2001; 161: 2685-2692.
  30. Peters AL. Clinical relevance of non-HDL cholesterol in patients with diabetes. Clinial Diabetes 2008;26:3-7.
  31. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship be-tween plasma glucose and HbA1c: analysis of glucose profiles and HbA1c in the Diabetes Control and Com-plications trial. Diabetes Care 2002; 25: 275-278.
  32. Khan HA, Sobki SH, Khan SA. Association between glycaemic control and serum lipids profile in type 2 diabetic patients: HbA1c predicts dyslipidaemia. Clin Exp Med 2007; 7: 24-29.
  33. Selvin E, Wattanakit K, Steffes MW, Coresh J, Sharrett AR. HbA1c and peripheral arterial disease in diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care 2006; 29: 877-882.
  34. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Pro-spective Investigation of Cancer and Nutrition (EPIC-Norfolk). Br Med J 2001; 322: 15-18.

Correspondence to:
Ram Vinod Mahato

Department of Biochemistry
Peoples Dental College & Hospital
Kathmandu, Nepal

Access free medical resources from Wiley-Blackwell now!

About Indmedica - Conditions of Usage - Advertise On Indmedica - Contact Us

Copyright © 2005 Indmedica